ReviewNeurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics2009
Multifunctional actions of approved and candidate stroke drugs.
Review in Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Exploring Erythropoietin and G-CSF Combination Therapy in Chronic Stroke Patients.International journal of molecular sciences · 2016Trial
- Citicoline: pharmacological and clinical review, 2022 update.Revista de neurologia · 2022Review
- Four Decades of Ischemic Penumbra and Its Implication for Ischemic Stroke.Translational stroke research · 2021Review
- Novel approaches for the delivery of therapeutics in ischemic stroke.Drug discovery today · 2020Review
- Neuroprotective mechanisms of erythropoietin in a rat stroke model.Translational neuroscience · 2020Article
- Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity.Scientific reports · 2016Article
- Increasing the Biological Stability Profile of a New Chemical Entity, UPEI-104, and Potential Use as a Neuroprotectant Against Reperfusion-Injury.Brain sciences · 2015Article
- Neuroprotective effect of penehyclidine hydrochloride on focal cerebral ischemia-reperfusion injury.Neural regeneration research · 2013Article
- miRNAs-19b, -29b-2* and -339-5p show an early and sustained up-regulation in ischemic models of stroke.PloS one · 2013Article
- Article
- NSAIDs in the treatment and/or prevention of neurological disorders.Inflammopharmacology · 2012Review
- Characterization of neuroprotective effects of biphalin, an opioid receptor agonist, in a model of focal brain ischemia.The Journal of pharmacology and experimental therapeutics · 2011Article
- Sinomenine protects against ischaemic brain injury: involvement of co-inhibition of acid-sensing ion channel 1a and L-type calcium channels.British journal of pharmacology · 2011Article
- Growth factors in ischemic stroke.Journal of cellular and molecular medicine · 2011Review
- Erythropoietin for stroke treatment: dead or alive?Critical care (London, England) · 2011Article
- Methodological quality of preclinical stroke studies is not required for publication in high-impact journals.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2010Article
- EPO for stroke therapy - Is there a future for further clinical development?Experimental & translational stroke medicine · 2010Article
- Intracarotid administration of human bone marrow mononuclear cells in rat photothrombotic ischemia.Experimental & translational stroke medicine · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ischemic stroke causes brain damage by multiple pathways. Previous stroke trials have demonstrated that drugs targeting one or only a few of these pathways fail to improve clinical outcome after stroke. Drugs with multimodal actions have been suggested to overcome this challenge. In this review, we describe the mechanisms of action of agents approved for secondary prevention of ischemic stroke, such as antiplatelet, antihypertensive, and lipid-lowering drugs. These drugs exhibit considerable properties beyond their classical mechanisms, including neuroprotective and neuroregenerative properties. In addition, candidate stroke drugs currently studied in clinical phase III trials are described. Among these, albumin, hematopoietic growth factors, and citicoline have been identified as promising agents with multiple mechanisms. These drugs offer hope that additional treatment options for the acute phase after a stroke will become available in the near future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.